The Market and Potential for Molecular Point of Care Diagnostics: Forecasts to 2018

Attention: There is an updated edition available for this report.
 
   Single User - $2,995



Loading...
Published Feb 5, 2014 | 245 Pages | Pub ID: KLI5201690

The Market and Potential for Molecular Point of Care Diagnostics

Molecular Point of Care is a budding field in medical diagnostics. Kalorama's report, The Market and Potential for Molecular Point of Care Diagnostics, provides the most current look at this field.  

To assess the opportunity, Kalorama's report examines the molecular diagnostics business and also the point-of-care (POC) diagnostics business as they are now, and then examines at the new combination products.   A good number of companies are producing or considering molecular diagnostic platforms and assays that are made for near-patient or POC testing, and the earliest of these systems are starting to reach the market. The business focus for most of these companies is initially on infectious disease testing, in which rapid test results generate important data that physicians can utilize in making treatment decisions.  

Included in the report is the following:
  • Company portraits for IVD Companies with POC MDX products.
  • Industry Estimates for Market Opportunity Based on Existing Markets, 2013-2018 
  • Expenditure in Molecular POC
  • Microbiology Diagnostics Opportunities 
  • Relevant Accords in Molecular
  • Purchases of Competitors with Near-Patient Solutions
  • Relevant Accords in POC 
  • Analyst Conclusions on Future Trends
POC and Moleuclar are two of the strongest growth segments of the overall IVD industry.  These once were different industry segments, but this is no longer true.  Interest has grown in developing molecular diagnostic platforms that can be used in POC settings.   Indeed, as this new industry research report from Kalorama outlines, the emerging niche of rapid molecular POC testing has attracted almost $700 million in financing in just five years.  

This report presents information derived from publicly available sources such as company reports and announcements, government reports and databases, medical organization reports, medical association announcements, and other publications. The assessment is based on the analyst’s industry knowledge combined with literature searches and discussions with industry pros and experts in the areas of POC testing, decentralized healthcare, and healthcare economics.

Almost 100 competitors involved in this industry are profiled in this report, including the following:
  • Abacus Diagnostica Oy 
  • Access Bio, Inc. 
  • Biocartis SA 
  • BioFire Diagnostics, Inc. 
  • bioMérieux sa 
  • Cepheid 
  • MBio Diagnostics, Inc. 
  • Meridian Bioscience, Inc. 
  • Micronics Inc. (A Sony Group Company) 
  • Molbio Diagnostics Pvt. Ltd. 
  • Nanosphere, Inc. 
  • NetBio, Inc. 
  • NorChip 
  • OptiGene Ltd. 
  • PositiveID Corporation 
  • QIAGEN N.V 
  • Wave 80 Biosciences 
  • Xagenic Inc.
  • and many others 
In this report,  {{key}} appears {{searchResults.reportMatchCounts[value]}} times
We were unable to search inside this report.
No results matched your search criteria.

Search for an exact word or phrase by placing the word or phrase in quotation marks ("market trend"). Search for different versions or tenses of a word by placing an asterisk at the end of the word (pharma*).

Please note that your term must be at least three characters long and numbers will be blocked by the # sign.